TRD205 / Sino Biopharm - LARVOL DELTA

Efficacy and Safety of TRD205 Tablets for Postoperative Analgesia in Unilateral Total Hip Arthroplasty (Phase IIb) (clinicaltrials.gov) - P2 | N=200 | Recruiting | Sponsor: Beijing Tide Pharmaceutical Co., Ltd

New P2 trial • Orthopedics

TRD205-II-02: To Evaluate the Safety, Efficacy and Kinetic Characteristics of TRD205 Tablets for Postoperative Analgesia After Unilateral Hip Arthroplasty (clinicaltrials.gov) - P2 | N=40 | Not yet recruiting | Sponsor: Beijing Tide Pharmaceutical Co., Ltd

New P2 trial • Orthopedics

To Evaluate the Efficacy and Safety of TRD205 Tablets in the Treatment of Chronic Postoperative Neuralgia (clinicaltrials.gov) - P2 | N=184 | Enrolling by invitation | Sponsor: Beijing Tide Pharmaceutical Co., Ltd

New P2 trial • Neuralgia • Pain

To Evaluate the Safety, Efficacy and Kinetic Characteristics of TRD205 Tablets for Postoperative Analgesia After Unilateral Hallux Valgus Orthopedic Surgery (clinicaltrials.gov) - P1 | N=32 | Not yet recruiting | Sponsor: Beijing Tide Pharmaceutical Co., Ltd

New P1 trial • Orthopedics

Global First-in-Class AT2R Antagonist TRD205 Advances to Phase II: First Patient Dosed in Chronic Post-Surgical Neuropathic Pain Trial (The Manila Times) - "Beijing Tide Pharmaceutical Co., Ltd...has achieved a milestone in developing its first-in-class analgesic drug (research code: TRD205), a highly selective angiotensin II type 2 receptor (AT2R) antagonist, with the first patient successfully dosed. As the first globally innovative drug targeting chronic post-surgical neuropathic pain (CPSP) to enter Phase II clinical development, TRD205 is positioned to overcome the limitations of existing opioid therapies and provide a safer, more effective solution for hundreds of millions of patients worldwide."

Trial status • Pain